Results 71 to 80 of about 5,674 (178)

Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals

GMS Ophthalmology Cases, 2016
We report a patient with a bilateral optic anterior ischemic neuropathy as an extrahepatic complication of a chronic hepatitis C (HCV) infection. The patient presented with a bilateral visual acuity loss and bilateral optic disc oedema.
Prud’homme, Sylvie, Nevens, Frederik, Casteels, Ingele   +2 more
doaj   +1 more source

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

, 2015
OBJECTIVE: To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. DESIGN: In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults
Esmat G, BRUNETTO, MAURIZIA ROSSANA, Lawitz, Eric J, Esmat, Gamal, McPhee, Fiona, Zeuzem S, Weiland O, Sievert, William, Pockros, Paul J, Sievert W, Serfaty, Lawrence, Hirschfield GM, Rodriguez Torres M, Everson, Gregory T, Wind Rotolo M, Waked I, Hernandez D, Rustgi VK, Bourlière M, Shafran, Stephen D, Ghesquiere, Wayne, McPhee F, Kwo, Paul Y, Vierling JM, Ghesquiere W, Bräu, Norbert, Schnittman, Steven, Thuluvath PJ, Noviello S, Sulkowski, Mark, Fried, Michael W, Hézode C, Rodriguez-Torres, Maribel, Pol S, Bourlière, Marc, Brunetto, Maurizia R, Pockros PJ, Hirschfield, Gideon M, Serfaty L, Everson GT, Hughes EA, Hézode, Christophe, Yin PD, Bräu N, Hernandez, Dennis, Liu Z, Lawitz EJ, Noviello, Stephanie, Kwo PY, Weiland, Ola, Weis, Nina, Waked, Imam, Liu, Zhaohui, Tatum, Harvey A, Yin, Philip D, Sulkowski M, Thuluvath, Paul J, Fried MW, Tatum HA, Schnittman S., Shafran SD, Weis N, Pol, Stanislas, Rustgi, Vinod K, Hughes, Eric A, Wind-Rotolo, Megan, Vierling, John M, Zeuzem, Stefan   +67 more
core   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, Volume 56, Issue 5, Page 778-783, May 2026.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Daclatasvir [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS

Pakistan Armed Forces Medical Journal, 2020
Objective: To evaluate the efficacy of sofosbuvir with daclatasvir and its promising effects on liver functions especially in respect to earlier treatment failure patients to frame an appropriate regimen for them.
Sumetha Yaseen, Kulsoom Farhat, Mahwish Gul, Syeda Urooj Zaidi, Maryam Saqib, Ayman Zafar   +5 more
doaj  

The Impact of Hepatitis C and Socio‐Demographic Variables on Health‐Related Quality of Life in Pakistan: Cross‐Sectional Study

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Approximately 8.8 million people are living with chronic hepatitis C virus (HCV) in Pakistan. We assessed factors related to health‐related quality of life (HRQoL) among the general population screened for HCV and calculated the national burden in quality‐adjusted life years (QALYs).
Siwaporn Niyomsri, Aaron G. Lim, Ambreen Arif, Muhammad Asim, Auj Chaudhry, Naheed Choudhry, Aliya Hasnain, Polychronis Kemos, Chris Metcalfe, Asad Choudhry, Saeed Sadiq Hamid, Saad Niaz, Huma Qureshi, Graham R. Foster, Peter Vickerman, Josephine G. Walker, HepFreePak team, Aqsa Ramzan, Atif Saghir, Ejaz Alam, Ghayas Hai, Mohd Saadullah, Muhammad Nabeel Shafqat, Muhammad Sufyan Tahir, Taha Khan   +24 more
wiley   +1 more source

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

, 2018
Amro M Hassan,1 Heba A Osman,2 Hasan S Mahmoud,2 Mohammed H Hassan,3 Abdel-Kader A Hashim,4 Hesham H Ameen5 1Tropical Medicine Department, Faculty of Medicine, Al-Azhar University (Assiut Branch), Assiut, Egypt; 2Tropical Medicine and Gastroenterology ...
Osman HA, Ameen HH, Hassan MH, Hashim AA, Hassan AM, Mahmoud HS   +5 more
core  

Evaluation of the effi cacy and safety of the use of asunaprevir in combination with daclatasvir in patients with chronic hepatitis С: a prospective cohort study

Медицинский вестник Юга России, 2017
Objective: to give assessment of the effi cacy and safety of using asunaprevir in combination with daclatasvir in patients with chronic hepatitis C (HCV) with severe fi brosis and cirrhosis.
Elena B. Romanova, Yuri M. Ambalov, Dmitry V. Sizyakin, Irina Y. Khomenko, Oleg I. Khomenko, Karina R. Titiryan   +5 more
doaj   +1 more source